for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Bridget Keenan, PhD
Headshot of Bridget Keenan
Bridget Keenan



This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

Official Title

A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas


This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. Dose Escalation Phase: Approximately 40-50 subjects with a maximum number of 62; Dose Expansion Phase: Estimated 100-400 subjects depending on the number of cohorts to be expanded.


Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma, Solid tumor, lymphoma, bispecific, antibody, Lymphoma, Neoplasms, Non-Hodgkin Lymphoma, B-Cell Lymphoma, ATG-101


You can join if…

Open to people ages 18 years and up

  1. Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
  2. Aged at least 18 years as of the date of consent.
  3. Histological or cytological confirmation of a solid tumor, and has progressed despite standard therapy, or is intolerant to standard therapy, or has a tumor for which no standard therapy exists or for which standard therapy is not considered adequate. Estimated life expectancy of a minimum of 12 weeks.
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  5. Female and male subjects should be using adequate contraceptive measures as requested.

You CAN'T join if...

  1. Subjects with CNS tumors or known CNS metastases will be excluded.
  2. Prior ATG-101 administration or a 4-1BB agonist.
  3. Prior anti-tumor systemic therapy within 21 days(a period of 5 'half- lives') of the first dose of study treatment.
  4. Radiotherapy with a wide field of radiation within 28 days.
  5. With the exception of alopecia, any unresolved toxicities from prior therapy greater than Grade 1 (CTCAE v5.0) at the time of ICF signature.
  6. Active infection, including hepatitis B and/or hepatitis C.
  7. Have uncontrolled intercurrent illness, including but not limited to:
  8. Inadequate bone marrow reserve or organ function.
  9. History of hypersensitivity or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to ATG-101.

    10. Prior organ allograft transplantations. 11. Pregnant or nursing females. 12. Have a history of another primary malignancy within 3 years prior to starting study

    treatment. Exceptions are as follows: the disease under study; adequately treated basal or squamous cell carcinoma of the skin; cancer of the cervix in situ, etc.

    13. In the opinion of the investigator, subject's complications or other conditions may

    affect protocol compliance or may be unsuitable for participation in the study.


  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Washington University School of Medicine in St. Louis accepting new patients
    Saint Louis Missouri 63110 United States

Lead Scientist at UCSF

  • Bridget Keenan, PhD
    I am a physician scientist who works in translational cancer research and medical oncology. My clinical practice is in the Cancer Immunotherapy Clinic, where I work with patients with solid organ cancers who are being treated on early phase immunotherapy trials. I also attend on the Oncology Consult inpatient service.


accepting new patients
Start Date
Completion Date
Antengene Biologics Limited
Phase 1 research study
Study Type
Expecting 40 study participants
Last Updated